by 21 CFR 5.20, finds that Mr. Gary D. Mays has been convicted of conspiracy to commit a felony under Federal law for conduct relating to the regulation of a drug product under the act and that the type of conduct which served as the basis for his conviction undermines the process for the regulation of drugs (21 U.S.C. 335a(b)(2)(B)(i)(II)).

As a result of the foregoing finding, and due to the nature and seriousness of his offense, Mr. Gary D. Mays is debarred for a period of 5 years from providing services in any capacity to a person that has an approved or pending drug product application under sections 505, 507, 512, or 802 of the act (21 U.S.C. 355, 357, 360b, or 382), or biological product license application or establishment license application under section 351 of the Public Health Service Act (42 U.S.C. 262), effective January 24, 1997 (21 U.S.C. 335a(c)(1)(B) and (c)(2)(A)(iii)). In addition, FDA will not accept or review any abbreviated new drug application or abbreviated antibiotic drug application from Mr. Mays during his period of debarment (21 U.S.C. 335a(c)(1)(B)). Any person with an approved or pending drug product application including, but not limited to, a biological product license application or an establishment license application, who knowingly uses the services of Mr. Mays in any capacity during his period of debarment will be subject to civil money penalties (21 U.S.C. 335b(a)(6)). If Mr. Mays during his period of debarment provides services in any capacity to a person with an approved or pending drug product application including, but not limited to, a biological product license application or an establishment license application, he will be subject to civil money penalties (21 U.S.C. 335b(a)(7)).

Any application by Mr. Mays for termination of debarment under section 306(d)(4) of the act should be identified with the docket number found in brackets in the heading of this notice and sent to the Dockets Management Branch (address above). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: January 7, 1997.

Kathryn C. Zoon,

*Director, Center for Biologics Evaluation and Research.*

[FR Doc. 97–1784 Filed 1–23–97; 8:45 am]

BILLING CODE 4160–01–F

**[Docket No. 95N–253M]**

## Cigarettes and Smokeless Tobacco; Notice of Public Meetings

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public meetings.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that it will hold 10 public meetings to promote understanding of, and encourage proper compliance with, FDA's final regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents. The meetings will focus on those provisions of the final rule that will take effect February 28, 1997 (see the ''SUPPLEMENTARY INFORMATION'' section in this document). FDA officials will be present at these meetings to explain the new regulations, and will be available to answer questions.

**DATES:** See Table 1 in the ''SUPPLEMENTARY INFORMATION'' section of this document.

**ADDRESSES:** See Table 1 in the ''SUPPLEMENTARY INFORMATION'' section of this document.

**FOR FURTHER INFORMATION CONTACT:** See Table 1 in the ''SUPPLEMENTARY INFORMATION'' section of this document.

**SUPPLEMENTARY INFORMATION:** In the Federal Register of August 28, 1996 (61 FR 44396), FDA published a final rule to restrict the sale and distribution of cigarettes and smokeless tobacco in order to protect children and adolescents. These regulations address the serious public health problem caused by cigarettes and smokeless tobacco products. The goal of the final rule is to reduce children's and adolescents' easy access to cigarettes and smokeless tobacco and to decrease significantly the amount of positive imagery that makes these products so appealing to children.

The provisions in the final rule have different effective dates. Starting February 28, 1997, Federal regulations will prohibit retailers from selling cigarettes, cigarette tobacco, or smokeless tobacco to any person under the age of 18, and will require retailers to check the photographic identification of every person under the age of 27 who wishes to purchase such a product to verify that the purchaser is at least 18 years old. Under the current schedule, starting August 28, 1997, the remaining provisions of the rule will become effective, except for the sponsorship provision, which will become effective on August 28, 1998.

The meetings will be held at the addresses and on the dates listed in Table 1 and are scheduled to last 1 hour.

There is no charge to attend these meetings. Advance registration is requested because seating is limited. The deadline for registering is 1 week before each meeting. Registration will be accepted so long as space is available. Late registration will be accepted only if space is available. Persons interested in attending should mail or telephone their name, organization, address, and telephone number to FDA's contact persons listed in Table 1 for each meeting location.

TABLE 1

| Meeting Address | Date and Local Time | FDA Contact Person |
|---|---|---|
| BALTIMORE: Baltimore Sheraton Inner Harbor Hotel, 300 South Charles St., Baltimore, MD. | February 11, 1997, Tuesday 11 a.m. to 12 m. | Leonard Genova, 900 Madison Ave., Baltimore, MD, 21201, 410–962–3731 |
| BOSTON: Park Plaza Hotel, Plaza Ballroom, 64 Arlington St., Boston, MA. | February 11, 1997, Tuesday 10 a.m. to 11 a.m. | Paula Fairfield, One Montvale Ave., Stoneham, MA, 02810, 617–279–1675, ext. 184 |
| DETROIT: Harper Hospital, 3990 John Rd., Detroit, MI. | February 12, 1997, Wednesday 1:30 p.m. to 2:30 p.m. | Evelyn DeNike, 1560 East Jefferson, Detroit, MI, 48207, 313–226–6158 |

TABLE 1—Continued

| Meeting Address | Date and Local Time | FDA Contact Person |
|---|---|---|
| CHICAGO: Marriott Hotel, 8535 West Higgins Rd., Chicago, IL. | February 13, 1997, Thursday 1 p.m. to 2 p.m. | Darlene Bailey, 300 South Riverside Plaza, suite 550 South, Chicago, IL, 60606, 312–353–7126 |
| BOULDER: National Institute of Standards and Technology, 325 Broadway, Boulder, CO. | February 19, 1997, Wednesday 10 a.m. to 11 a.m. | Virlie Walker, P.O. Box 25087, Denver Federal Center, Denver, CO, 80225–0087, 303–236–3018 |
| MIAMI: Crown Plaza Miami, 1601 Biscayne Blvd., Miami, FL. | February 19, 1997, Wednesday 10:30 a.m. to 11:30 a.m. | Estela Niella-Brown, P.O. Box 59–2256, Miami, FL, 33159–2256, 305–526–2800, ext. 937 |
| ATLANTA: Sheraton Colony Square, 188 14th St. NE., Atlanta, GA. | February 20, 1997, Thursday 10 a.m. to 11 a.m. | Sheila Bayne-Lisby (ext. 5231) and Jo Ann Pittman (ext. 5340), 60 Eighth St. NE., Atlanta, GA, 30309, 404–347–4001 |
| HOUSTON: Holiday Inn/Hobby Airport, 9100 Gulf Freeway, Houston, TX. | February 20, 1997, Thursday 10:30 a.m. to 11:30 a.m. | Sheryl Lunnon Baylor, 1445 North Loop West, suite 420, Houston, TX, 77008, 713–802–9095, ext. 15 |
| LOS ANGELES: Omni Los Angeles Hotel, 930 Wilshire Blvd., Los Angeles, CA. | February 25, 1997, Tuesday 11 a.m. to 12 m. | Rosario Vior, 19900 MacArthur Blvd., suite 300, Irvine, CA, 92612–2445, 714–798–7607 |
| SEATTLE: Lopez Room at Seattle Center, 305 Harrison St., Seattle, WA. | February 26, 1997, Wednesday 11 a.m. to 12 m. | Susan Hutchcroft, 22201 23rd Dr. SE., Bothell, WA, 98041, 206–486–8788 |

Dated: January 17, 1997.

William K. Hubbard,

*Associate Commissioner for Policy Coordination.*

[FR Doc. 97–1718 Filed 1–21–97; 3:06 pm]

**BILLING CODE 4160–01–F**

## National Institutes of Health

### Proposed Collection; Comment Request; Case-Control Study of Cancer and Related Disorders Among Benzene-Exposed Workers in China

**SUMMARY:** In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**PROPOSED COLLECTION:** *Title:* Case-Control Study of Cancer and Related Disorders Among Benzene-Exposed Workers in China. *Type of Information Collection Request:* New. *Need and Use of Information Collection:* A case-control study will examine the relationship between exposure to benzene and the risk of lymphohematopoietic malignancies and related disorders and lung cancer in Chinese workers. Cases and controls will be selected from participants in a recent cohort study of benzene-exposed workers in China. The data will be used by the NCI to examine risk among workers exposed to low levels of benzene, and to characterize the dose and time-specific relationship between benzene exposure and disease risk. *Frequency of Response:* One-time study. *Affected Public:* Individuals or households. *Type of Respondents:* Workers. The annual reporting burden is a follows: *Estimated Number of Respondents:* 1,545; *Estimated Number of Responses per Respondent:* One; *Average burden hours per Response:* 0.75; and *Estimated Total Annual Burden Hours Requested:* 386.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

**REQUEST FOR COMMENTS:** Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection or information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Richard Hayes, Project Officer, National Cancer Institute, Executive Plaza North, Room 418, Rockville, Maryland 20892–7364, or call non-toll-free number (301) 496–9093, or FAX your request to (301) 402–1819, or E-mail your request, including your address, to HayesR@epndce.nci.nih.gov.

**COMMENTS DUE DATE:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: January 16, 1997.

Nancy L. Bliss,

*OMB Project Clearance Liaison.*

[FR Doc. 97–1709 Filed 1–23–97; 8:45 am]

**BILLING CODE 4140–01–M**

### Office of the Director; Notice of Meeting

Pursuant to sec. 10(d) of the Federal Advisory Committee Act (FACA), as amended (Title 5, U.S.C. Appendix 2) notice is hereby given of the meeting of the Alternative Medicine Program Advisory Council on February 10, 1997 from 8:30 a.m. to 5 p.m. and on